Aurobindo Pharma Buyback: Last Date to Buy Shares Today Ahead of April 17 Record Date

Aurobindo Pharma has announced a share buyback programme valued at ₹800 crore, drawing attention from investors assessing participation. With the record date approaching, timing becomes important due to settlement rules. 

Investors planning to be eligible for the buyback must ensure shares are credited to their demat accounts within the stipulated timeframe.

Aurobindo Pharma Buyback Announcement and Key Details

The company disclosed its buyback plan on April 6, setting the buyback price at ₹1,475 per share. 

This represents a premium of over 7% compared to the previous closing price of ₹1,374. The buyback provides shareholders with an option to tender shares at a price above recent market levels.

Aurobindo Pharma Record Date and Eligibility Criteria

The record date to determine eligible shareholders has been fixed as April 17, 2026. Investors must hold shares in their demat accounts on this date to participate in the buyback process.

Aurobindo Pharma Last Date to Buy Shares

Due to the T+1 settlement cycle in Indian markets, April 16, 2026 is the last day investors can purchase shares to qualify for the buyback. Shares bought on this date are expected to be credited to demat accounts by the record date. Any purchases made after this deadline will not be considered eligible.

Aurobindo Pharma’s Share Price Performance

Aurobindo Pharma’s share price showed marginal movement in early trading on April 16, 2026. The stock was trading at ₹1,375.00 as of 10:14 AM IST, reflecting a modest gain of ₹1.10 or 0.08% compared to the previous close of ₹1,373.90.

Read More: LIC Share Price in Focus on Apr 13, 2026, Ahead of Board Meeting to Consider First Bonus Issue.

Conclusion

The Aurobindo Pharma buyback underlines the importance of aligning trade execution with settlement cycles. Investors must adhere to the April 16 deadline to meet the April 17 record date criteria for participation.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.